Adam Bonislawski

The report recommended against the use of markers including fetal fibronectin and Sera Prognostics' PreTRM test due to low positive predictive value.

The researchers found that the blood-based marker, a key product for vendor Quanterix, could aid in the diagnosis and management of several diseases.

FDA's approval of the Biogen anti-amyloid Alzheimer's drug could drive demand for new tests for the disease, including potentially C2N's blood-based assay.

The proteomics firm is working with four health providers to assess how its tests can improve delivery of care and to map out potential new use cases.

The test uses mass spectrometry to measure an M. tuberculosis peptide and could be used for diagnosing the disease and monitoring response to treatment.

The funds likely won't roll out on a large scale until fall, raising questions about what demand from schools will be, given vaccinations and falling infection rates.

The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.

The French biotech company has indicated that it will likely create a wholly owned subsidiary that will house its diagnostics work.

While increased POC and home testing could cut into the conventional lab business, it also fits with existing industry trends toward more patient-centered models.

Increased competition from point-of-care and home tests and the rollout of vaccines appear to be cutting into demand for lab-based molecular SARS-CoV-2 assays.